WO1993012756A3 - Transfection of lung via aerosolized transgene delivery - Google Patents

Transfection of lung via aerosolized transgene delivery Download PDF

Info

Publication number
WO1993012756A3
WO1993012756A3 PCT/US1992/011008 US9211008W WO9312756A3 WO 1993012756 A3 WO1993012756 A3 WO 1993012756A3 US 9211008 W US9211008 W US 9211008W WO 9312756 A3 WO9312756 A3 WO 9312756A3
Authority
WO
WIPO (PCT)
Prior art keywords
lung
transfection
transgene delivery
lung via
airway
Prior art date
Application number
PCT/US1992/011008
Other languages
French (fr)
Other versions
WO1993012756A2 (en
Inventor
Robert J Debs
Ning Zhu
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Priority to EP93901159A priority Critical patent/EP0619742B1/en
Priority to DE69232815T priority patent/DE69232815T2/en
Priority to JP5511786A priority patent/JPH07505134A/en
Priority to AU33291/93A priority patent/AU679170B2/en
Priority to CA002126103A priority patent/CA2126103C/en
Publication of WO1993012756A2 publication Critical patent/WO1993012756A2/en
Publication of WO1993012756A3 publication Critical patent/WO1993012756A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4712—Cystic fibrosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Abstract

Methods and compositions for producing a mammal capable of expressing an exogenously supplied gene in cells of the airway are disclosed. Lipid carrier-nucleic acid complexes are prepared then delivered via aerosol to the lung airway. The invention provides a direct method for transforming pulmonary cells as a means for treating disorders of the lung as for providing a means for delivering substances systematically following expression in the lung.
PCT/US1992/011008 1991-12-17 1992-12-17 Transfection of lung via aerosolized transgene delivery WO1993012756A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP93901159A EP0619742B1 (en) 1991-12-17 1992-12-17 Transfection of lung via aerosolized transgene delivery
DE69232815T DE69232815T2 (en) 1991-12-17 1992-12-17 LUNG TRANSFECTION BY ADMINISTRATION OF TRANSGENES IN AEROSOL
JP5511786A JPH07505134A (en) 1991-12-17 1992-12-17 Lung transfection by aerosolized injected gene delivery
AU33291/93A AU679170B2 (en) 1991-12-17 1992-12-17 Transfection of lung via aerosolized transgene delivery
CA002126103A CA2126103C (en) 1991-12-17 1992-12-17 Transfection of lung via aerosolized transgene delivery

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US80929191A 1991-12-17 1991-12-17
US07/809,291 1991-12-17
US07/972,135 US5858784A (en) 1991-12-17 1992-11-05 Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US07/972,135 1992-11-05

Publications (2)

Publication Number Publication Date
WO1993012756A2 WO1993012756A2 (en) 1993-07-08
WO1993012756A3 true WO1993012756A3 (en) 1994-09-01

Family

ID=27123206

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1992/011008 WO1993012756A2 (en) 1991-12-17 1992-12-17 Transfection of lung via aerosolized transgene delivery

Country Status (8)

Country Link
US (3) US5858784A (en)
EP (1) EP0619742B1 (en)
JP (2) JPH07505134A (en)
AU (1) AU679170B2 (en)
CA (1) CA2126103C (en)
DE (1) DE69232815T2 (en)
ES (1) ES2185624T3 (en)
WO (1) WO1993012756A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9018187B2 (en) 2009-07-01 2015-04-28 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
US9139554B2 (en) 2008-10-09 2015-09-22 Tekmira Pharmaceuticals Corporation Amino lipids and methods for the delivery of nucleic acids

Families Citing this family (363)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670488A (en) * 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US20020164782A1 (en) 1999-02-10 2002-11-07 Gregory Richard J. Adenovirus vectors for gene therapy
US8153602B1 (en) * 1991-11-19 2012-04-10 Isis Pharmaceuticals, Inc. Composition and methods for the pulmonary delivery of nucleic acids
US5693769A (en) * 1991-12-13 1997-12-02 Transcell Technologies, Inc. Glycosylated steroid derivatives for transport across biological membranes and process for making and using same
US5795870A (en) * 1991-12-13 1998-08-18 Trustees Of Princeton University Compositions and methods for cell transformation
EP0625207A1 (en) * 1991-12-17 1994-11-23 The Regents Of The University Of California Gene therapy for cystic fibrosis transmembrane conductance regulator activity (cftr)
US5858784A (en) * 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
WO1994005782A1 (en) * 1992-09-10 1994-03-17 Trustees Of Tufts College In vivo production of transgenic organ by introducing the transgene via lumen
JPH09500013A (en) 1993-06-01 1997-01-07 ライフ・テクノロジーズ・インコーポレイテッド Gene immunity with cationic lipids
US5688677A (en) * 1993-10-13 1997-11-18 Genzyme Corporation Deoxyribonucleic acids containing inactivated hormone responsive elements
US6887856B1 (en) 1993-10-15 2005-05-03 University Of Pittsburgh Protection from ionizing irradiation or chemotherapeutic drug damage by in vivo gene therapy
WO1995010538A1 (en) * 1993-10-15 1995-04-20 The University Of North Carolina At Chapel Hill Dna encoding the human p2u receptor and null cells expressing p2u receptors
FR2711523B1 (en) 1993-10-26 1996-02-16 Transgene Sa Process for the preparation of a viral aerosol.
US5614551A (en) * 1994-01-24 1997-03-25 The Johns Hopkins University Inhibitors of fatty acid synthesis as antimicrobial agents
US6995008B1 (en) 1994-03-07 2006-02-07 Merck & Co., Inc. Coordinate in vivo gene expression
US5670347A (en) 1994-05-11 1997-09-23 Amba Biosciences Llc Peptide-mediated gene transfer
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AUPM747694A0 (en) * 1994-08-16 1994-09-08 Commonwealth Scientific And Industrial Research Organisation Delivery of nucleic acids and peptides
FR2727679B1 (en) * 1994-12-05 1997-01-03 Rhone Poulenc Rorer Sa NEW TRANSFECTION AGENTS AND THEIR PHARMACEUTICAL APPLICATIONS
US6383814B1 (en) * 1994-12-09 2002-05-07 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
MX9704765A (en) * 1994-12-24 1998-02-28 Univ Cambridge Tech Improvements in or relating to endometrial function.
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US6008202A (en) * 1995-01-23 1999-12-28 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
FR2732895B1 (en) * 1995-04-11 1997-05-16 Pasteur Merieux Serums Vacc USE OF A CATIONIC AMPHIPATHIC COMPOUND AS A TRANSFECTING AGENT, AS A VACCINE ADDITIVE, OR AS A MEDICINAL PRODUCT
US5935568A (en) * 1995-05-18 1999-08-10 National Jewish Medical & Research Center Gene therapy for effector cell regulation
US5756122A (en) * 1995-06-07 1998-05-26 Georgetown University Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells
US7422902B1 (en) 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5981501A (en) * 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
AU771241B2 (en) * 1995-06-07 2004-03-18 Tekmira Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US7034007B1 (en) 1995-06-07 2006-04-25 East Carolina University Low adenosine anti-sense oligonucleotide, compositions, kit & method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) & surfactant depletion
EP1489184A1 (en) * 1995-06-07 2004-12-22 Inex Pharmaceutical Corp. Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US6025339A (en) * 1995-06-07 2000-02-15 East Carolina University Composition, kit and method for treatment of disorders associated with bronchoconstriction and lung inflammation
US5705385A (en) * 1995-06-07 1998-01-06 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US6825174B2 (en) 1995-06-07 2004-11-30 East Carolina University Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation
US5994315A (en) * 1995-06-07 1999-11-30 East Carolina University Low adenosine agent, composition, kit and method for treatment of airway disease
US6040296A (en) * 1995-06-07 2000-03-21 East Carolina University Specific antisense oligonucleotide composition & method for treatment of disorders associated with bronchoconstriction and lung inflammation
AU7078396A (en) * 1995-09-27 1997-04-30 Regents Of The University Of California, The Polyfunctional cationic cytofectins, formulations and methods for generating active cytofectin:polynucleotide transfection complexes
US5869715A (en) * 1995-09-27 1999-02-09 The Reagents Of The University Of California Polyfunctional cationic cytofectins
US6121247A (en) * 1996-03-29 2000-09-19 The Johns Hopkins University Therapy for allergic diseases
US6156567A (en) * 1996-07-03 2000-12-05 Merial Truncated transcriptionally active cytomegalovirus promoters
AU738838B2 (en) * 1996-09-12 2001-09-27 Valentis, Inc. Compositions and methods for pulmonary gene delivery
US6977244B2 (en) * 1996-10-04 2005-12-20 Board Of Regents, The University Of Texas Systems Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
CA2269825A1 (en) 1996-10-24 1998-04-30 Kenneth Brigham Gene delivery and expression in areas inaccessible to direct protein delivery
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US5980898A (en) * 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US20060002949A1 (en) * 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
US20060002959A1 (en) * 1996-11-14 2006-01-05 Government Of The United States Skin-sctive adjuvants for transcutaneous immuization
US5981575A (en) * 1996-11-15 1999-11-09 Johns Hopkins University, The Inhibition of fatty acid synthase as a means to reduce adipocyte mass
US6034072A (en) * 1997-02-10 2000-03-07 Genemedicine, Inc. IL-2 gene expression and delivery systems and uses
US7112338B2 (en) 1997-03-12 2006-09-26 The Regents Of The University Of California Cationic liposome delivery of taxanes to angiogenic blood vessels
US5837283A (en) 1997-03-12 1998-11-17 The Regents Of The University Of California Cationic lipid compositions targeting angiogenic endothelial cells
US5965542A (en) * 1997-03-18 1999-10-12 Inex Pharmaceuticals Corp. Use of temperature to control the size of cationic liposome/plasmid DNA complexes
US7262173B2 (en) * 1997-03-21 2007-08-28 Georgetown University Chemosensitizing with liposomes containing oligonucleotides
US6559129B1 (en) * 1997-03-21 2003-05-06 Georgetown University Cationic liposomal delivery system and therapeutic use thereof
US6126965A (en) * 1997-03-21 2000-10-03 Georgetown University School Of Medicine Liposomes containing oligonucleotides
US20030229040A1 (en) * 1997-03-21 2003-12-11 Georgetown University Cationic liposomal delivery system and therapeutic use thereof
US6235310B1 (en) 1997-04-04 2001-05-22 Valentis, Inc. Methods of delivery using cationic lipids and helper lipids
US5958894A (en) * 1997-04-04 1999-09-28 Megabios Corporation Amphiphilic biguanide derivatives
US5948925A (en) * 1997-05-06 1999-09-07 Genzyme Corporation Cationic amphiphiles containing linkers derived from neutral or positively charged amino acids
US5952516A (en) * 1997-05-08 1999-09-14 Genzyme Corporation Cationic amphiphiles containing multiplesteroid lipophilic groups
US5942634A (en) * 1997-05-09 1999-08-24 Genzyme Corporation Cationic amphiphiles for cell transfections
CA2205076A1 (en) 1997-05-14 1998-11-14 Jim Hu Episomal expression cassettes for gene therapy
US20090239940A1 (en) * 1997-07-22 2009-09-24 Del Monte Federica Treating heart failure and ventricular arrhythmias
DE69840361D1 (en) 1997-07-30 2009-01-29 Univ Emory NEW BONE MINERALIZATION PROTEINS, DNA, VECTORS, EXPRESSION SYSTEMS
US7923250B2 (en) 1997-07-30 2011-04-12 Warsaw Orthopedic, Inc. Methods of expressing LIM mineralization protein in non-osseous cells
US20050142126A1 (en) * 1997-08-20 2005-06-30 Bernard Knoops Peroxisome-associated polypeptide, nucleotide sequence encoding said polypeptide and their uses in the diagnosis and/or the treatment of lung injuries and diseases, and of oxidative stress-related disorders
WO1999015641A1 (en) 1997-09-24 1999-04-01 The Regents Of The University Of California Non-primate lentiviral vectors and packaging systems
US6946117B1 (en) 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US20060165606A1 (en) * 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US20020017295A1 (en) * 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6433040B1 (en) * 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US7285288B1 (en) 1997-10-03 2007-10-23 Board Of Regents, The University Of Texas System Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US7704962B1 (en) * 1997-10-03 2010-04-27 Board Of Regents, The University Of Texas System Small oligonucleotides with anti-tumor activity
US20040258703A1 (en) * 1997-11-14 2004-12-23 The Government Of The Us, As Represented By The Secretary Of The Army Skin-active adjuvants for transcutaneous immunization
US7157098B1 (en) * 1998-01-06 2007-01-02 Roman Perez-Soler Gene therapy of tumors using non-viral delivery system
TW520294B (en) * 1998-01-08 2003-02-11 Res Dev Foundation Stabilization of lipid: DNA formulations during nebulization
US6375980B1 (en) * 1998-01-08 2002-04-23 Research Development Foundation Stabilization of lipid:DNA formulations during nebulization
JP2002502831A (en) 1998-02-03 2002-01-29 イネックス ファーマシューティカルズ コーポレイション Systemic delivery of serum-stable plasmid lipid particles for the treatment of cancer
US6410328B1 (en) 1998-02-03 2002-06-25 Protiva Biotherapeutics Inc. Sensitizing cells to compounds using lipid-mediated gene and compound delivery
US6158431A (en) * 1998-02-13 2000-12-12 Tsi Incorporated Portable systems and methods for delivery of therapeutic material to the pulmonary system
US6221848B1 (en) 1998-05-11 2001-04-24 University Of Pittsburgh Protection of the esophagus from chemotherapeutic or irradiation damage by gene therapy
WO1999060166A1 (en) * 1998-05-21 1999-11-25 Isis Pharmaceuticals, Inc. Compositions and methods for the pulmonary delivery of nucleic acids
EP1086116A4 (en) * 1998-05-21 2004-03-17 Isis Pharmaceuticals Inc Compositions and methods for the pulmonary delivery of nucleic acids
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
US20040247662A1 (en) * 1998-06-25 2004-12-09 Dow Steven W. Systemic immune activation method using nucleic acid-lipid complexes
US6693086B1 (en) 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
CN1317009A (en) * 1998-08-03 2001-10-10 东卡罗来纳大学 Low adenosine anti-sense oligonucleotide agent, composition, reagent kit and treatments
DK1129064T3 (en) 1998-11-12 2008-04-28 Invitrogen Corp transfection
EP1839648A3 (en) * 1998-11-12 2007-11-21 Transave, Inc. An inhalation system
CN100358494C (en) * 1998-11-12 2008-01-02 弗兰克G·皮尔基威克兹 Inhalation system
US6855549B1 (en) 1998-11-23 2005-02-15 The University Of Iowa Research Foundation Methods and compositions for increasing the infectivity of gene transfer vectors
US6716810B1 (en) * 1998-12-09 2004-04-06 Eleanor Roosevelt Institute Composition and method for regulation of body weight and associated conditions
JP5620037B2 (en) * 1999-02-24 2014-11-05 ノース・キャロライナ・ステイト・ユニヴァーシティ Methods and compositions for altering mucus secretion
US8501911B2 (en) * 1999-02-24 2013-08-06 Biomarck Pharmaceuticals, Ltd Methods of reducing inflammation and mucus hypersecretion
US7544772B2 (en) 2001-06-26 2009-06-09 Biomarck Pharmaceuticals, Ltd. Methods for regulating inflammatory mediators and peptides useful therein
IL140054A0 (en) * 1999-04-06 2002-02-10 Univ East Carolina Low adenosine anti-sense oligonucleotide, compositions, kit and method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy (ies) and surfactant depletion
EP2368575B1 (en) * 1999-04-08 2014-10-01 Intercell USA, Inc. Dry formulation for transcutaneous immunization
AU7595000A (en) * 1999-09-23 2001-04-24 General Hospital Corporation, The Methods for potentiating antisense rna techniques
JP2003514855A (en) 1999-10-13 2003-04-22 チャコン，マルコ，エー． Therapeutic intervention mimicking the effects of calorie restriction
US7115712B1 (en) 1999-12-02 2006-10-03 Maxygen, Inc. Cytokine polypeptides
US7265088B1 (en) 2000-02-24 2007-09-04 North Carolina State University Method and compositions for altering mucus secretion
US7919469B2 (en) 2000-02-24 2011-04-05 North Carolina State University Methods and compositions for altering mucus secretion
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US8404217B2 (en) * 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
WO2001085136A2 (en) * 2000-05-10 2001-11-15 Alliance Pharmaceutical Corporation Phospholipid-based powders for drug delivery
US10293056B1 (en) * 2000-05-24 2019-05-21 Board Of Regents, The University Of Texas System Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
US20020106368A1 (en) * 2000-07-28 2002-08-08 Adrian Bot Novel methods and compositions to upregulate, redirect or limit immune responses to peptides, proteins and other bioactive compounds and vectors expressing the same
PT1372708E (en) * 2001-02-13 2008-09-29 Us Gov Sec Army Vaccine for transcutaneous immunization against travellers` diarrhoea
AU2002256398A2 (en) * 2001-04-30 2002-11-11 Targeted Genetics Corporation Lipid-comprising drug delivery complexes and methods for their production
WO2002087541A1 (en) * 2001-04-30 2002-11-07 Protiva Biotherapeutics Inc. Lipid-based formulations for gene transfer
AU2002314855B2 (en) * 2001-05-30 2007-08-09 Board Of Trustees Of The Leland Stanford, Jr., University Delivery system for nucleic acids
EP1424898A4 (en) * 2001-08-20 2008-04-02 Transave Inc Treatment of cancers by inhalation of stable platinum-containing formulations
US20030059375A1 (en) * 2001-08-20 2003-03-27 Transave, Inc. Method for treating lung cancers
US20040076966A1 (en) * 2001-10-30 2004-04-22 J. Brian Windsor Method and system for the co-isolation of cognate DNA, RNA and protein sequences and method for screening co-isolates for defined activities
CN101259289B (en) * 2001-11-02 2012-05-30 嵌入治疗公司 Methods and compositions for therapeutic use of RNA interference
IL161733A0 (en) 2001-11-02 2005-11-20 Insert Therapeutics Inc Methods and compositions for therapeutic use of rna interference
US20040063654A1 (en) * 2001-11-02 2004-04-01 Davis Mark E. Methods and compositions for therapeutic use of RNA interference
AUPR894201A0 (en) * 2001-11-19 2001-12-13 Women's And Children's Hospital Respiratory delivery for gene therapy and lentiviral delivery particle
JP2005514393A (en) * 2001-12-19 2005-05-19 ネクター セラピューティクス Supplying aminoglycosides to the lung
EP1487413A4 (en) * 2002-03-05 2010-11-10 Transave Inc An inhalation system for prevention and treatment of intracellular infections
AU2003278695A1 (en) * 2002-05-28 2004-02-02 Maxygen, Inc. Nucleic acid vectors
EP2338478B1 (en) 2002-06-28 2014-07-23 Protiva Biotherapeutics Inc. Method for producing liposomes
US9186322B2 (en) * 2002-08-02 2015-11-17 Insmed Incorporated Platinum aggregates and process for producing the same
MXPA05001312A (en) * 2002-08-02 2005-08-03 Transave Inc Platinum aggregates and process for producing the same.
US7718189B2 (en) 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
US7879351B2 (en) * 2002-10-29 2011-02-01 Transave, Inc. High delivery rates for lipid based drug formulations, and methods of treatment thereof
PT2363114E (en) * 2002-10-29 2015-07-02 Insmed Inc Sustained release of antiinfectives
KR20050067216A (en) * 2002-11-01 2005-06-30 코핀 코포레이션 Multi-domain vertical alignment liquid crystal display
SI2656854T1 (en) 2003-02-04 2015-09-30 Cornell Research Foundation, Inc. Uses of aromatic-cationic peptide
KR101161823B1 (en) 2003-05-01 2012-07-03 코넬 리서치 화운데이션,인크. Method and carrier complexes for delivering molecules to cells
WO2005020885A2 (en) * 2003-05-21 2005-03-10 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
WO2005004913A1 (en) * 2003-07-09 2005-01-20 Anges Mg, Inc. Pharmaceutical composition containing decoy and method of using the same
WO2005007196A2 (en) 2003-07-16 2005-01-27 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
WO2005023292A1 (en) 2003-09-03 2005-03-17 The General Hospital Corporation Methods of treating restenosis
NZ581166A (en) 2003-09-15 2011-06-30 Protiva Biotherapeutics Inc Polyethyleneglycol-modified lipid compounds and uses thereof
PL1687066T3 (en) 2003-11-14 2013-01-31 Brigham & Womens Hospital Inc Methods of modulating immunity
KR20060123413A (en) * 2003-12-03 2006-12-01 추가이 세이야쿠 가부시키가이샤 EXPRESSION SYSTEM WITH THE USE OF MAMMALIAN beta;-ACTIN PROMOTER
US8592368B2 (en) * 2003-12-19 2013-11-26 University Of South Florida JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection
NZ549393A (en) 2004-01-23 2009-07-31 Cornell Res Foundation Inc Methods for reducing oxidative damage
CA2553714A1 (en) * 2004-01-23 2005-08-04 Keio University Support accumulating in injured part in vascular channel
US20060019914A1 (en) * 2004-02-11 2006-01-26 University Of Tennessee Research Foundation Inhibition of tumor growth and invasion by anti-matrix metalloproteinase DNAzymes
US20050181035A1 (en) * 2004-02-17 2005-08-18 Dow Steven W. Systemic immune activation method using non CpG nucleic acids
US20070065522A1 (en) * 2004-03-18 2007-03-22 Transave, Inc. Administration of high potency platinum compound formulations by inhalation
CN1976711A (en) * 2004-03-18 2007-06-06 特兰萨维股份有限公司 Administration of cisplatin by inhalation
CA2566174A1 (en) * 2004-05-21 2005-12-01 Transave, Inc. Treatment of lung diseases and pre-lung disease conditions
CA2569645C (en) 2004-06-07 2014-10-28 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use
WO2005121348A1 (en) 2004-06-07 2005-12-22 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
WO2006002538A1 (en) 2004-07-02 2006-01-12 Protiva Biotherapeutics, Inc. Immunostimulatory sirna molecules and uses therefor
US20060051405A1 (en) * 2004-07-19 2006-03-09 Protiva Biotherapeutics, Inc. Compositions for the delivery of therapeutic agents and uses thereof
US20060045849A1 (en) * 2004-08-24 2006-03-02 Farhan Taghizadeh Method of customizing the fragrance of nasal medications
EP1811963A4 (en) * 2004-11-08 2010-01-06 Transave Inc Methods of treating cancer with lipid-based platinum compound formulations administered intraperitoneally
WO2006053430A1 (en) * 2004-11-17 2006-05-26 Protiva Biotherapeutics, Inc. Sirna silencing of apolipoprotein b
MX2007008744A (en) 2005-01-20 2008-03-10 Biomarck Pharmaceuticals Ltd Mucin hypersecretion inhibitors based on the structure of mans and methods of use.
EP1858542A4 (en) * 2005-02-24 2009-08-19 Joslin Diabetes Center Inc Compositions and methods for treating vascular permeability
EP1866414B9 (en) 2005-03-31 2012-10-03 Calando Pharmaceuticals, Inc. Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
UA95446C2 (en) 2005-05-04 2011-08-10 Іллюміджен Байосайєнсіз, Інк. Mutations in oas1 genes
US20070031342A1 (en) * 2005-06-22 2007-02-08 Nektar Therapeutics Sustained release microparticles for pulmonary delivery
US20110178092A1 (en) * 2005-06-22 2011-07-21 Akbar Ali HIV-1 Protease Inhibitors
US20070054873A1 (en) * 2005-08-26 2007-03-08 Protiva Biotherapeutics, Inc. Glucocorticoid modulation of nucleic acid-mediated immune stimulation
CN103784937B (en) 2005-09-16 2017-04-26 科内尔研究基金会 Methods for reducing CD36 expression
EP1951737A4 (en) * 2005-11-01 2009-07-01 Alnylam Pharmaceuticals Inc Rnai inhibition of influenza virus replication
EP2395012B8 (en) 2005-11-02 2018-06-06 Arbutus Biopharma Corporation Modified siRNA molecules and uses thereof
US20070190182A1 (en) * 2005-11-08 2007-08-16 Pilkiewicz Frank G Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
US9107824B2 (en) 2005-11-08 2015-08-18 Insmed Incorporated Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
EP3067047B1 (en) 2005-12-08 2022-04-20 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections
WO2007092944A2 (en) * 2006-02-08 2007-08-16 Introgen Therapeutics, Inc. Compositions and methods involving gene therapy and proteasome modulation
EP2441770A1 (en) 2006-02-10 2012-04-18 The University of Cincinnati Phosphatase inhibitor protein-1 as a regulator of cardiac function
KR100745833B1 (en) 2006-03-06 2007-08-02 고려대학교 산학협력단 Complex composition of cationic gold nanoparticles and dna for effective transfection
EP1993611A4 (en) * 2006-03-16 2013-05-22 Alnylam Pharmaceuticals Inc RNAi MODULATION OF TGF-BETA AND THERAPEUTIC USES THEREOF
WO2007123777A2 (en) * 2006-03-30 2007-11-01 Duke University Inhibition of hif-1 activation for anti-tumor and anti-inflammatory responses
US20090317335A1 (en) * 2006-04-20 2009-12-24 Wenbin Lin Hybrid Nanomaterials as Multimodal Imaging Contrast Agents
EP2023937B1 (en) 2006-05-19 2011-10-12 Alnylam Pharmaceuticals Inc. Rnai modulation of aha and therapeutic uses thereof
US7915399B2 (en) 2006-06-09 2011-03-29 Protiva Biotherapeutics, Inc. Modified siRNA molecules and uses thereof
ZA200900550B (en) * 2006-07-26 2010-03-31 Biomarck Pharmaceuticals Ltd Methods for attenuating release of inflammatory mediators and peptides useful therein
KR100825519B1 (en) * 2007-01-05 2008-04-25 주식회사 바이오폴리메드 A chitosan based polymer conjugate and a method for producing the same
WO2008137717A1 (en) 2007-05-04 2008-11-13 Transave, Inc. Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods and uses thereof
US9114081B2 (en) 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
EP3000320B1 (en) 2007-05-16 2019-01-16 The Brigham and Women's Hospital, Inc. Treatment of synucleinopathies
CN101939019B (en) 2008-02-07 2014-07-16 康奈尔大学 Methods for preventing or treating insulin resistance
US20110135571A1 (en) * 2008-02-22 2011-06-09 Wenbin Lin Hybrid nanoparticles as anti-cancer therapeutic agents and dual therapeutic/imaging contrast agents
EP2262520B1 (en) 2008-02-26 2017-05-03 Cornell University Compositions for prevention and treatment of renal injury
BRPI0911332A2 (en) 2008-04-04 2019-09-24 Calando Pharmaceuticals Inc compositions and use of epas1 inhibitors
EP2862871A1 (en) 2008-04-14 2015-04-22 The General Hospital Corporation Plectin-1 targeted agents for detection and treatment of pancreatic ductal adenocarcinoma
PL2279254T3 (en) 2008-04-15 2017-11-30 Protiva Biotherapeutics Inc. Novel lipid formulations for nucleic acid delivery
CA2729303A1 (en) 2008-06-30 2010-01-14 Angioblast Systems, Inc. Treatment of eye diseases and excessive neovascularization using a combined therapy
US20110208064A1 (en) 2008-07-31 2011-08-25 Ran Chongzhao Curcumin Derivatives for Amyloid-Beta Plaque Imaging
WO2010051530A2 (en) 2008-10-31 2010-05-06 The General Hospital Corporation Compositions and methods for delivering a substance to a biological target
EP2344519B1 (en) 2008-11-07 2016-09-28 The General Hospital Corporation C-terminal fragments of glucagon-like peptide-1 (glp-1)
TW201031436A (en) * 2009-02-16 2010-09-01 Univ Nat Taiwan Pharmaceutical composition for inhalation delivery and fabrication method thereof
WO2010105096A2 (en) 2009-03-11 2010-09-16 University Of Massachusetts Modulation of human cytomegalovirus replication by micro-rna 132 (mir132), micro-rna 145 (mir145) and micro-rna 212 (mir212)
CN103933542A (en) 2009-03-20 2014-07-23 通用医疗公司以马萨诸塞州通用医疗公司名义经营 Methods For The Prevention And Treatment Of Burn Injuries And Secondary Complications
JP2010251707A (en) * 2009-03-27 2010-11-04 Fujitsu Ltd Wiring board, and semiconductor device
EP2756845B1 (en) 2009-04-03 2017-03-15 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA
EP2449114B9 (en) 2009-07-01 2017-04-19 Protiva Biotherapeutics Inc. Novel lipid formulations for delivery of therapeutic agents to solid tumors
US8569256B2 (en) 2009-07-01 2013-10-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
EP3427746A1 (en) 2009-08-12 2019-01-16 Cornell University Methods for preventing or treating metabolic syndrome
SI3708178T1 (en) 2009-08-24 2024-01-31 Stealth Biotherapeutics Inc. Peptide for use in preventing or treating macular degeneration
US20120208750A1 (en) 2009-09-29 2012-08-16 Joslin Diabetes Center, Inc. Use of protein kinase c delta (pkcd) inhibitors to treat diabetes, obesity, and hepatic steatosis
EP2485749A4 (en) * 2009-10-05 2013-07-24 Univ Cornell Methods for the prevention or treatment of heart failure
NZ600616A (en) 2009-12-01 2014-11-28 Shire Human Genetic Therapies Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
EP3090754A1 (en) 2009-12-31 2016-11-09 Stealth Peptides International, Inc. Methods for the prevention or treatment of vessel occlusion injury
US20130190244A1 (en) 2009-12-31 2013-07-25 Stealth Peptides International, Inc. Methods for performing a coronary artery bypass graft procedure
CN102834408A (en) 2010-01-25 2012-12-19 康奈尔大学 Aromatic-cationic peptides and uses of same
WO2011106525A2 (en) 2010-02-26 2011-09-01 The Brigham And Women's Hospital, Inc. Methods of treating cerebral amyloid angiopathy
EP3210615A1 (en) 2010-03-15 2017-08-30 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides
CN103038256A (en) 2010-04-29 2013-04-10 纳斯瓦克斯有限公司 Methods and compositions for treating hepatitis with anti-CD3 immune molecule therapy
EP2942354A1 (en) 2010-05-03 2015-11-11 Stealth Peptides International, Inc. Aromatic-Cationic Peptides and Uses of Same
WO2012000104A1 (en) 2010-06-30 2012-01-05 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
EP4285994A3 (en) 2010-07-09 2024-01-17 Stealth BioTherapeutics Inc. Methods for the prevention or treatment of no-reflow following ischemia/reperfusion injury
WO2012050673A1 (en) 2010-10-14 2012-04-19 Wisconsin Alumni Research Foundation Methods for the treatment of x-linked hypophosphatemia and related disorders
US9447027B2 (en) 2010-10-22 2016-09-20 The General Hospital Corporation Treating long QT syndrome
WO2012065182A2 (en) 2010-11-12 2012-05-18 University Of Massachusetts Modulation of ubiquitination of synaptic proteins for the treatment of neurodegenerative and psychiatric disorders
EP3211001B1 (en) 2010-12-22 2020-10-07 The Board of Trustees of the Leland Stanford Junior University Superagonists and antagonists of interleukin-2
CN103796665B (en) 2011-03-24 2018-10-30 康奈尔大学 Aromatic-cationic peptides and application thereof
EP2691515A2 (en) 2011-03-31 2014-02-05 President and Fellows of Harvard College A unique population of regulatory t cells that regulate tissue regeneration and wound healing
EP2729157B1 (en) 2011-07-06 2019-01-16 The General Hospital Corporation A pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1) for use in treatment
JP6049712B2 (en) 2011-07-08 2016-12-21 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒルＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｎｏｒｔｈ Ｃａｒｏｌｉｎａ Ａｔ Ｃｈａｐｅｌ Ｈｉｌｌ Metal bisphosphonate nanoparticles for anti-cancer treatment and imaging and bone disorder treatment
CN107496899A (en) 2011-09-29 2017-12-22 梅约医学教育与研究基金会 Aromatic-cationic peptide and use their method
GB201118704D0 (en) * 2011-10-28 2011-12-14 Univ Oxford Cystic fibrosis treatment
EP2780456A1 (en) 2011-11-17 2014-09-24 The U.S.A. as represented by the Secretary, Department of Health and Human Services Therapeutic rna switches compositions and methods of use
EP3466439A1 (en) 2011-12-09 2019-04-10 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
US20150018288A1 (en) 2012-02-22 2015-01-15 Stealth Peptides International, Inc. Methods and compositions for preventing or treating ophthalmic conditions
AU2013222237B2 (en) 2012-02-23 2017-10-05 Cornell University Aromatic-cationic peptides and uses of same
WO2013138338A2 (en) 2012-03-12 2013-09-19 Massachusetts Institute Of Technology Methods for treating tissue damage associated with ischemia with apoliporotein d
US9534059B2 (en) 2012-04-13 2017-01-03 Children's Medical Center Corporation TIKI inhibitors
KR102277921B1 (en) 2012-05-21 2021-07-14 인스메드 인코포레이티드 Systems for treating pulmonary infections
CN104519915A (en) * 2012-06-08 2015-04-15 夏尔人类遗传性治疗公司 Pulmonary delivery of mRNA to non-lung target cells
EP3662921A1 (en) 2012-08-02 2020-06-10 Stealth Peptides International, Inc. D-arg-2'6'-dmt-lys-phe-nh2 for decreasing statin side effects
WO2014025808A1 (en) 2012-08-06 2014-02-13 The General Hospital Corporation Curcumin analogs
DK2892524T3 (en) 2012-09-04 2021-01-25 Eleison Pharmaceuticals LLC PREVENTION OF PULMONAL CANCER RECYCLING WITH LIPID-COMPLEXED CISPLATIN
PE20151434A1 (en) 2012-10-22 2015-10-16 Stealth Peptides Int Inc METHODS FOR THE REDUCTION OF RISKS ASSOCIATED WITH HEART FAILURE AND FACTORS ASSOCIATED WITH IT
US9902705B2 (en) 2012-10-24 2018-02-27 The General Hospital Corporation Functionalized 1,2,4,5-tetrazine compounds for use in bioorthogonal coupling reactions
AU2013352259B2 (en) 2012-11-29 2018-06-14 Insmed Incorporated Stabilized vancomycin formulations
WO2014088631A1 (en) 2012-12-06 2014-06-12 Stealth Peptides International, Inc. Peptide therapeutics and methods for using same
EP3789022A1 (en) 2012-12-27 2021-03-10 Massachusetts Eye & Ear Infirmary Treatment of rhinosinusitis with p-glycoprotein inhibitors
US9770426B2 (en) 2013-01-11 2017-09-26 Massachusetts Eye And Ear Infirmary CYP450 lipid metabolites reduce inflammation and angiogenesis
EP2851086A1 (en) 2013-09-20 2015-03-25 Sanofi Serpins: methods of therapeutic ß-cell regeneration and function
EP2769732A1 (en) 2013-02-22 2014-08-27 Sanofi Serpins: methods of therapeutic beta-cell regeneration and function
US20160002316A1 (en) 2013-02-22 2016-01-07 Joslin Diabetes Center Serpins: methods of therapeutic beta-cell regeneration and function
DK2961378T3 (en) 2013-03-01 2019-11-25 Stealth Biotherapeutics Corp METHODS OF TREATING MITOCHONDRIC DISEASE
CN115990242A (en) 2013-03-01 2023-04-21 康德生物医疗有限公司 Methods and compositions for preventing or treating Bass syndrome
US9757468B2 (en) 2013-03-13 2017-09-12 The Regents Of The University Of California Intranasal administration of guanidinylated aminoglycosides
US9981038B2 (en) 2013-03-13 2018-05-29 The General Hospital Corporation Photoswitchable HDAC inhibitors
AR095426A1 (en) 2013-03-14 2015-10-14 Onyx Therapeutics Inc TRIPEPTIDE INHIBITORS OF PROTEASA EPOXYCETONE
WO2014152127A1 (en) 2013-03-14 2014-09-25 Onyx Therapeutics, Inc. Dipeptide and tripeptide epoxy ketone protease inhibitors
EP2971153B1 (en) 2013-03-15 2018-10-10 The General Hospital Corporation Glycine, mitochondrial one-carbon metabolism, and cancer
EP3586864A1 (en) 2013-05-14 2020-01-01 Stealth Biotherapeutics Corp Methods for the prevention or treatment of left ventricle remodeling
US9737525B2 (en) 2013-06-07 2017-08-22 The General Hospital Corporation Small molecule activators of NRF2 pathway
US9884085B2 (en) 2013-06-26 2018-02-06 Stealth Biotherapeutics Corp Methods for the regulation of matrix metalloproteinase expression
CA2916977A1 (en) 2013-06-26 2014-12-31 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions
CA2916486A1 (en) 2013-06-26 2015-01-22 Stealth Biotherapeutics Corp Methods and compositions comprising an aromatic peptide for regulating serca2a expression levels in myocardinal infarction
US10293020B2 (en) 2013-06-27 2019-05-21 Stealth Biotherapeutics Corp. Peptide therapeutics and methods for using same
CA2920020C (en) 2013-08-02 2023-03-14 Stealth Biotherapeutics Corp Methods and compositions for the prevention and treatment of friedreich's ataxia
WO2015034996A1 (en) 2013-09-06 2015-03-12 The General Hospital Corporation Imaging brown adipose tissue with curcumin derivatives
CA2925421C (en) 2013-09-24 2023-08-29 Medicenna Therapeutics, Inc. Interleukin-2 fusion proteins and uses thereof
WO2015069926A1 (en) 2013-11-06 2015-05-14 The University Of Chicago Nanoscale carriers for the delivery or co-delivery of chemotherapeutics, nucleic acids and photosensitizers
CN105939759B (en) 2013-12-02 2020-01-17 康德生物医疗技术公司 Compositions and methods for treating vitiligo
WO2015103643A2 (en) 2014-01-06 2015-07-09 The General Hospital Corporation Integrin antagonists
US10300070B2 (en) 2014-03-27 2019-05-28 The Brigham And Women's Hospital, Inc. Metabolically-activated drug conjugates to overcome resistance in cancer therapy
EP3134102B1 (en) 2014-04-24 2019-07-03 The Board of Trustees of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
ES2820226T3 (en) 2014-05-15 2021-04-20 Insmed Inc Methods for treating nontuberculous mycobacterial lung infections
WO2015175846A2 (en) 2014-05-16 2015-11-19 University Of Massachusetts Treating chronic myelogenous leukemia (cml)
EP3148565A4 (en) 2014-05-28 2018-06-06 Stealth Biotherapeutics Corp Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof
CA2950410A1 (en) 2014-05-28 2015-12-03 D. Travis Wilson Therapeutic compositions including therapeutic small molecules and uses thereof
US9668996B2 (en) 2014-06-04 2017-06-06 Tersus Life Sciences, LLC Methods of treating chronic dry eye disease using C16:1n7-palmitoleate and derivatives thereof
CN106536056B (en) 2014-06-13 2021-07-16 儿童医学中心公司 Products and methods for isolating mitochondria
WO2015195737A1 (en) 2014-06-17 2015-12-23 Stealth Peptides International, Inc. Methods of identifying and monitoring mitochondrial dysfunction using monocyte screening
CN106572974B (en) 2014-07-15 2021-04-23 生命技术公司 Compositions and methods having lipid aggregates for efficient delivery of molecules to cells
WO2016025480A1 (en) 2014-08-11 2016-02-18 The General Hospital Corporation Cyclooctenes for bioorthogonol reactions
EP3903802A1 (en) 2014-08-21 2021-11-03 Stealth Biotherapeutics Corp Peptide d-arg-2',6'-dmt-lys-phe-nh2 for treating alport syndrome
JO3474B1 (en) 2014-08-29 2020-07-05 Amgen Inc Tetrahydronaphthalene derivatives that inhibit mcl-1 protein
US10806694B2 (en) 2014-10-14 2020-10-20 The University Of Chicago Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof
JP6731404B2 (en) 2014-10-14 2020-07-29 ザ ユニバーシティ オブ シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiation therapy, chemotherapy, immunotherapy, and any combination thereof
WO2016077232A2 (en) 2014-11-10 2016-05-19 Forge Life Science, Llc Anti-hcmv compositions and methods
EP3218356B1 (en) 2014-11-10 2022-11-30 Evrys Bio, LLC Anti-hcmv compositions and methods
US10420826B2 (en) 2014-11-11 2019-09-24 Massachusetts Eye & Ear Infirmary Conjunctivitis vaccines
DK3569711T3 (en) 2014-12-15 2021-02-22 Dicerna Pharmaceuticals Inc LIGAND MODIFIED DOUBLE STRING NUCLEIC ACIDS
AU2016206965B2 (en) 2015-01-12 2021-03-04 Children's Medical Center Corporation Pro-inflammatory and adjuvant functions of toll-like receptor 4 antagonists
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
EP3280451B8 (en) 2015-04-08 2019-09-25 The United States of America, as represented by the Secretary, Department of Health and Human Services Viral gene therapy as treatment for cholesterol storage disease or disorder
AU2016256895B2 (en) 2015-05-07 2022-05-26 Takeda Pharmaceutical Company Limited Glucocerebrosidase gene therapy for parkinson's disease
US20180296537A1 (en) 2015-06-05 2018-10-18 Novartis Ag Methods and compositions for diagnosing, treating, and monitoring treatment of shank3 deficiency associated disorders
CA2996635A1 (en) 2015-09-09 2017-03-16 Novartis Ag Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules
US10000561B2 (en) 2015-09-09 2018-06-19 Novartis Ag Thymic stromal lymphopoietin (TSLP)-binding molecules and methods of using the molecules
WO2017059338A1 (en) 2015-10-02 2017-04-06 Cornell University Enzyme-responsive peptide nanofiber compositions and uses thereof
WO2017066712A2 (en) 2015-10-16 2017-04-20 The Children's Medical Center Corporation Modulators of telomere disease
US11001622B2 (en) 2015-11-19 2021-05-11 The Brigham And Women's Hospital, Inc. Method of treating autoimmune disease with lymphocyte antigen CD5-like (CD5L) protein
JOP20200228A1 (en) 2015-12-21 2017-06-16 Novartis Ag Compositions and methods for decreasing tau expression
CN116196388A (en) 2016-01-06 2023-06-02 康德生物医疗有限公司 Methods and compositions for preventing and treating duchenne muscular dystrophy
WO2017123933A1 (en) 2016-01-15 2017-07-20 Massachusetts Eye And Ear Infirmary Secreted p-glycoprotein is a non-invasive biomarker of chronic rhinosinusitis
WO2017147410A1 (en) 2016-02-25 2017-08-31 Amgen Inc. Compounds that inhibit mcl-1 protein
EP3458159A4 (en) 2016-05-19 2019-12-18 Stealth BioTherapeutics Corp Compositions and methods for the prevention and treatment of mitochondrial myopathies
US11246877B2 (en) 2016-05-20 2022-02-15 The University Of Chicago Nanoparticles for chemotherapy, targeted therapy, photodynamic therapy, immunotherapy, and any combination thereof
US10981980B2 (en) 2016-06-15 2021-04-20 Counterpoint Biomedica Llc Polypeptide targeting aptamers for characterization, capture, and clinical management of circulating tumor cells
US10449230B2 (en) 2016-10-06 2019-10-22 The Regents Of The University Of California Polymyxin derived cell penetrating scaffolds
WO2018089688A1 (en) 2016-11-09 2018-05-17 Jinjun Shi Restoration of tumor suppression using mrna-based delivery system
JP2020500020A (en) 2016-11-14 2020-01-09 ノバルティス アーゲー Compositions, methods, and therapeutic uses related to the fusogenic protein MINION
AU2017371217B2 (en) 2016-12-09 2020-03-19 Akston Biosciences Corporation Insulin-Fc fusions and methods of use
US20200054660A1 (en) 2016-12-09 2020-02-20 St. Jude Children's Research Hospital Dna methylation profiling for t-cell immunotherapy
US10913779B2 (en) 2017-01-25 2021-02-09 Counterpoint Biomedica Llc Exposed collagen-targeted fusion cytokine for immune modulation in invasive cancers and lesions of infections
JP6453507B2 (en) 2017-03-30 2019-01-16 アムジエン・インコーポレーテツド Compound that inhibits MCL-1 protein
CA3067909A1 (en) 2017-06-19 2018-12-27 Medicenna Therapeutics Inc. Uses and methods for il-2 superagonists, agonists, and fusions thereof
WO2018237066A1 (en) 2017-06-20 2018-12-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Codon-optimized human npc1 genes for the treatment of niemann-pick type c1 deficiency and related conditions
EP3644964B1 (en) 2017-06-28 2024-04-10 Children's Medical Center Corporation Promoting lung growth
JP2020530986A (en) 2017-07-27 2020-11-05 ノバルティス アーゲー Shedase-resistant TREM2 mutant
BR102017016440A2 (en) * 2017-07-31 2019-03-19 Universidade Federal Do Rio Grande Do Sul COMPOSITION FOR CENTRAL NERVOUS SYSTEM GENE THERAPY, OBTAINING AND USE PROCESS
CN111194232B (en) 2017-08-02 2023-01-31 芝加哥大学 Nanoscale metal-organic layer and metal-organic nanosheet
MX2020001546A (en) 2017-08-08 2020-08-03 Memorial Sloan Kettering Cancer Center Use of braf inhibitors for treating cutaneous reactions caused by treatment with a mek inhibitor.
WO2019033114A1 (en) 2017-08-11 2019-02-14 Dana-Farber Cancer Institute, Inc. Use of a botulinum toxin agent for treating plasma cell disorders
US11821003B2 (en) 2017-08-14 2023-11-21 Sanford Burnham Prebys Medical Discovery Institute Cardiogenic mesoderm formation regulators
MA49908A (en) 2017-08-18 2021-04-28 Amgen Inc MCL-1 PROTEIN INHIBITORS
WO2019046150A1 (en) 2017-08-29 2019-03-07 Amgen Inc. Macrocyclic compounds that inhibit mcl-1 protein
WO2019046668A1 (en) 2017-08-31 2019-03-07 Kezar Life Sciences Amide substituted thiazoles as protein secretion inhibitors
BR112020007879A2 (en) 2017-10-18 2020-10-13 Evrys Bio, Llc broad-spectrum antiviral compositions and methods
AU2018388529A1 (en) 2017-12-18 2020-06-18 The General Hospital Corporation Glycoengineering
WO2019143969A1 (en) 2018-01-18 2019-07-25 Claudio Maldonado Treating microvascular dysfunction
US20210363587A1 (en) 2018-02-07 2021-11-25 St. Jude Children's Research Hospital EPIGENETIC HISTONE REGULATION MEDIATED BY CXorf67
WO2019169202A1 (en) 2018-02-28 2019-09-06 The Johns Hopkins University Bacterial biofilms and cancer
MA54985A (en) 2018-03-05 2021-12-29 Amgen Inc ALPHA-HYDROXY PHENYLACETIC ACID PHARMACOPHORES OR ANTAGONISTS OF BIOISOSTERY MCL-1 PROTEIN
JP7460534B2 (en) 2018-03-30 2024-04-02 インスメッド インコーポレイテッド Continuous manufacturing method for liposome medicines
US20190314324A1 (en) 2018-04-13 2019-10-17 The University Of Chicago Combination of micheliolide derivatives or nanoparticles with ionizing radiation and checkpoint inhibitors for cancer therapy
CN112424352A (en) 2018-05-11 2021-02-26 阿尔法阿诺麦里克公司 Oligonucleotide conjugates comprising 7 '-5' -alpha-anomeric bicyclic sugar nucleosides
KR20210021016A (en) 2018-06-13 2021-02-24 암피스타 테라퓨틱스 엘티디 Bifunctional molecules for Rpn11 targeting
WO2019238886A1 (en) 2018-06-13 2019-12-19 University Of Dundee Bifunctional molecules for targeting usp14
KR20210020107A (en) 2018-06-13 2021-02-23 암피스타 테라퓨틱스 엘티디 Bifunctional molecules for targeting UchL5
WO2020012331A1 (en) 2018-07-09 2020-01-16 St. Jude Children's Research Hospital Use of il-12 to alter epigenetic effector programs in cd8 t cells
WO2020023806A1 (en) 2018-07-25 2020-01-30 The Johns Hopkins University Compositions and methods for generation of heart field-specific progenitor cells
US20210292766A1 (en) 2018-08-29 2021-09-23 University Of Massachusetts Inhibition of Protein Kinases to Treat Friedreich Ataxia
UY38407A (en) 2018-10-15 2020-05-29 Novartis Ag TREM2 STABILIZING ANTIBODIES
FI3866799T3 (en) 2018-10-16 2024-02-29 Univ Johns Hopkins Compositions for treating vascular ehlers danlos syndrome
EP3876977A1 (en) 2018-11-06 2021-09-15 The Regents Of The University Of California Chimeric antigen receptors for phagocytosis
ES2961003T3 (en) 2018-12-06 2024-03-07 Stealth Biotherapeutics Inc D-Arg-2'6'-Dmt-Lys-Phe-NH2 for use in the treatment or prevention of Sengers syndrome
WO2020170231A1 (en) 2019-02-22 2020-08-27 St. Jude Children's Research Hospital Methods for identifying and improving t cell multipotency
MX2021010314A (en) 2019-02-28 2021-11-12 Kezar Life Sciences Thiazole derivatives as protein secretion inhibitors.
US20220395531A1 (en) 2019-04-15 2022-12-15 Children`S Medical Center Corporation Aerosolized compositions comprising mitochondria and methods of use thereof
GB2598520A (en) 2019-05-28 2022-03-02 Univ Shanghai Tech Composition and methods to treat ectodermal dysplasia 2, Clouston type
CN114466656A (en) 2019-07-24 2022-05-10 康德生物医疗有限公司 Peptidomimetic compounds (R) -2-amino-N- ((S) -1- (((S) -5-amino-1- (3-benzyl-1, 2, 4-oxadiazol-5-yl) pentyl) amino) -3- (4-hydroxy-2, 6-xylyl) -1-oxopropan-2-yl) -5-guanidinopentanamide in the treatment of neurodegenerative disorders
CN114746430A (en) 2019-10-04 2022-07-12 康德生物医疗有限公司 Quinone-, hydroquinone-and naphthoquinone-analogues of vattinoquinone for the treatment of mitochondrial disorders
AU2020367532A1 (en) 2019-10-17 2022-05-12 Ginkgo Bioworks, Inc. Adeno-associated viral vectors for treatment of Niemann-Pick disease type C
EP4090674A4 (en) 2020-01-14 2024-01-24 Synthekine Inc Biased il2 muteins methods and compositions
JP2023511274A (en) 2020-01-14 2023-03-17 シンセカイン インコーポレイテッド IL2 orthologs and usage
TW202140550A (en) 2020-01-29 2021-11-01 瑞士商諾華公司 Methods of treating an inflammatory or obstructive airway disease using anti-tslp antibody
AU2021246142A1 (en) 2020-04-03 2022-10-20 Stealth Biotherapeutics Inc. Compositions and methods for the prevention and/or treatment of mitochondrial disease, including Friedreich's ataxia
JP2023522933A (en) 2020-04-23 2023-06-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Genetically engineered phagocytic cells and related compositions, vectors, methods and systems
JP2023535792A (en) 2020-07-30 2023-08-21 ティジアーナ ライフ サイエンシズ パブリック リミティド カンパニー Anti-CD3 antibody for coronavirus therapy
JP2023536654A (en) 2020-08-05 2023-08-28 シンセカイン インコーポレイテッド IL10Ra binding molecules and methods of use
CA3190415A1 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Il2rb/il2rg synthetic cytokines
IL300736A (en) 2020-08-31 2023-04-01 Kezar Life Sciences Protein secretion inhibitors
AU2021376354A1 (en) 2020-11-04 2023-06-22 Myeloid Therapeutics, Inc. Engineered chimeric fusion protein compositions and methods of use thereof
CA3200234A1 (en) 2020-11-25 2022-06-02 Daryl C. Drummond Lipid nanoparticles for delivery of nucleic acids, and related methods of use
CN117396502A (en) 2021-02-09 2024-01-12 佐治亚大学研究基金会有限公司 Human monoclonal antibodies to pneumococcal antigens
AU2022365121A1 (en) 2021-10-14 2024-04-18 The Brigham And Women's Hospital, Inc. Methods of suppressing microglial activation
WO2023069255A1 (en) 2021-10-20 2023-04-27 Stealth Biotherapeutics Inc. Methods and compositions comprising peptidomimitics for treating, preventing, inhibiting, ameliorating or delaying the onset of ophthalmic conditions
WO2023101963A2 (en) 2021-11-30 2023-06-08 Northwestern University Compositions for inhibiting dipeptide repeat protein-ribosomal rna interaction and uses thereof
WO2023133321A1 (en) 2022-01-10 2023-07-13 Stealth Biotherapeutics Inc. Small molecule peptidomimetic for the treatment of tauopathies
WO2023164250A1 (en) 2022-02-28 2023-08-31 Kezar Life Sciences Sec61 inhibitors and use thereof
WO2023198757A1 (en) 2022-04-14 2023-10-19 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Alpha-1-antitrypsin for treating paramyxoviridae or orthomyxoviridae infections
GB202214445D0 (en) * 2022-09-30 2022-11-16 Imp College Innovations Ltd Gene therapy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4804678A (en) * 1982-01-22 1989-02-14 Fisons Plc Method for treating allergic conditions
WO1991006309A1 (en) * 1989-11-03 1991-05-16 Vanderbilt University Method of in vivo delivery of functioning foreign genes
EP0446017A1 (en) * 1990-03-05 1991-09-11 Genzyme Corporation New diagnostic and treatment methods involving the cystic fibrosis transmembrane regulator

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB354126A (en) * 1929-10-29 1931-08-06 Lucas Haendel Method and device for the production of cigarettes with tobacco coverings
US3826255A (en) * 1972-06-22 1974-07-30 Hudson Oxygen Therapy Sales Co Intermittent positive pressure breathing manifold
YU41046B (en) * 1974-08-22 1986-10-31 Schering Ag Medicine inholating device
US4268460A (en) * 1977-12-12 1981-05-19 Warner-Lambert Company Nebulizer
US4394448A (en) * 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4253468A (en) * 1978-08-14 1981-03-03 Steven Lehmbeck Nebulizer attachment
US4510929A (en) * 1982-04-30 1985-04-16 Bordoni Maurice E Disposable radioactive aerosol inhalation apparatus
US4649911A (en) * 1983-09-08 1987-03-17 Baylor College Of Medicine Small particle aerosol generator for treatment of respiratory disease including the lungs
US4946787A (en) * 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5049386A (en) * 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
DE3545126A1 (en) * 1985-12-19 1987-06-25 Boehringer Mannheim Gmbh METHOD FOR IMPROVING THE EXPRESSION OF EUKARYON PROTEIN
US5032407A (en) * 1987-01-16 1991-07-16 Ohio University Edison Animal Biotechnology Center Gene transfer using transformed, neodetermined, embryonic cells
EP0281246A3 (en) * 1987-02-04 1989-07-12 Invitron Corporation Method to enhance amplification and expression of foreign genes
US5075229A (en) * 1987-06-16 1991-12-24 Ohio University Edison Animal Biotechnology Center Dietary and hormonal regulation of expression of exogenous genes in transgenic animals under control of the promoter of the gene for phosphoenolpyruvate carboxykinase
JP2779192B2 (en) * 1987-09-17 1998-07-23 マサチユセツツ・インスチチユート・オブ・テクノロジー Human erythrocyte-specific transcription enhancer
IL90514A (en) * 1988-06-03 1995-10-31 Us Health Fusion gene comprising a multi-drug resistance gene fused to an adenine deaminase gene
US4923949A (en) * 1988-08-03 1990-05-08 Kanegafuchi Chemical Industry Co., Ltd. Ethynylene-disilanylene copolymers and method of preparing same
JPH04507041A (en) * 1988-12-13 1992-12-10 アメリカ合衆国 Endothelial cells modified by genetic engineering and methods for their use
WO1990010448A2 (en) * 1989-03-07 1990-09-20 Genentech, Inc. Covalent conjugates of lipid and oligonucleotide
ATE277193T1 (en) * 1989-03-21 2004-10-15 Vical Inc EXPRESSION OF EXOGENEOUS POLYNUCLEOTIDE SEQUENCES IN VERTEBRATES
GB8909218D0 (en) * 1989-04-22 1989-06-07 Medical Res Council Improvements in or relating to enhancers
US5240842A (en) * 1989-07-11 1993-08-31 Biotechnology Research And Development Corporation Aerosol beam microinjector
GB9020632D0 (en) * 1990-09-21 1990-10-31 Hsc Res Dev Corp Stable propagation of modified full length cystic fibrosis transmembrane conductance regulator protein cdna in heterologous systems
ATE253633T1 (en) * 1989-08-22 2003-11-15 Hsc Res Dev Corp CYSTIC FIBROSIS GEN
US5240846A (en) * 1989-08-22 1993-08-31 The Regents Of The University Of Michigan Gene therapy vector for cystic fibrosis
US5676954A (en) 1989-11-03 1997-10-14 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US5279833A (en) * 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
ATE126442T1 (en) * 1990-05-18 1995-09-15 Boehringer Ingelheim Int NEW PROTEIN POLYCATION CONJUGATES.
IT1246763B (en) 1990-07-11 1994-11-26 Frattini Costr Mecc HOT DRAWING PROCEDURE, ESPECIALLY ON EXTRUDED OR DRAWN BODIES OBTAINED IN ALUMINUM AND EQUIPMENT FOR THE IMPLEMENTATION OF THE PROCEDURE
JPH04252128A (en) * 1990-08-03 1992-09-08 Systemix Inc Denatured heterograft organ system in immunized host
AU1922092A (en) * 1991-05-03 1992-12-21 Albert Einstein College Of Medicine Of Yeshiva University Targeted delivery of genes encoding cell surface receptors
WO1993003709A1 (en) * 1991-08-16 1993-03-04 Vical, Inc. Composition and method for treating cystic fibrosis
EP0666923A1 (en) * 1991-09-05 1995-08-16 The University Of Connecticut Targeted delivery of poly- or oligonucleotides to cells
US5858784A (en) * 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
EP0625207A1 (en) * 1991-12-17 1994-11-23 The Regents Of The University Of California Gene therapy for cystic fibrosis transmembrane conductance regulator activity (cftr)
EP0646178A1 (en) * 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4804678A (en) * 1982-01-22 1989-02-14 Fisons Plc Method for treating allergic conditions
WO1991006309A1 (en) * 1989-11-03 1991-05-16 Vanderbilt University Method of in vivo delivery of functioning foreign genes
EP0446017A1 (en) * 1990-03-05 1991-09-11 Genzyme Corporation New diagnostic and treatment methods involving the cystic fibrosis transmembrane regulator

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BRIGHAM ET AL.: "Rapid communication: In vivo transfection of murine lungs with functioning prokaryotic gene using liposome vehicle", AM. J. MED. SCI., vol. 298, October 1989 (1989-10-01), pages 278 - 281, XP002089779 *
HUBBARD ET AL.: "Fate of aerosolized recombinant DNA-produced alpha1-antitrypsin: Use of the epithelial surface of the lower respiratory tract to administer proteins of therapeutic importance", PNAS, vol. 86, January 1989 (1989-01-01), USA, pages 680 - 684, XP000942146 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9139554B2 (en) 2008-10-09 2015-09-22 Tekmira Pharmaceuticals Corporation Amino lipids and methods for the delivery of nucleic acids
US9018187B2 (en) 2009-07-01 2015-04-28 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents

Also Published As

Publication number Publication date
US5641662A (en) 1997-06-24
EP0619742A1 (en) 1994-10-19
JPH07505134A (en) 1995-06-08
US5858784A (en) 1999-01-12
AU679170B2 (en) 1997-06-26
US6468798B1 (en) 2002-10-22
WO1993012756A2 (en) 1993-07-08
AU3329193A (en) 1993-07-28
DE69232815D1 (en) 2002-11-21
JP2002003383A (en) 2002-01-09
DE69232815T2 (en) 2003-09-18
EP0619742B1 (en) 2002-10-16
ES2185624T3 (en) 2003-05-01
CA2126103C (en) 2002-12-03
CA2126103A1 (en) 1993-07-08
EP0619742A4 (en) 1997-06-04

Similar Documents

Publication Publication Date Title
WO1993012756A3 (en) Transfection of lung via aerosolized transgene delivery
PL335353A1 (en) Humidity regulators containing kit for use in conjuntion with tissue paper products
WO1998019709A3 (en) Cationic reagents for transfection
AU4306896A (en) Method for the preparation of a viral vector by intermolecular homologous recombination
AU2259392A (en) Drug delivery of antisense oligonucleotides and peptides to tissues in vivo and to cells using avidin-biotin technology
CA2304975A1 (en) Stabilized preparations for use in metered dose inhalers
AU6649198A (en) Method and system for generating displays in relation to the play of baccarat
WO1999039741A3 (en) Systemic delivery of serum stable plasmid lipid particles for cancer therapy
HK1016653A1 (en) Riit cirtex specific gene promoter.
EP0759694A4 (en) Method for in vivo delivery of therapeutic agents via liposomes
AU7123296A (en) Liposomal formulations of mitoxantrone
Maziere et al. Tumor necrosis factor enhances low density lipoprotein oxidative modification by monocytes and endothelial cells
CA2098483A1 (en) Safe adeno-associated virus 2 vector for gene therapy
AU5311596A (en) Preparation of sodium chloride aerosol formulations
WO2004050027A3 (en) Materials and methods for treating ocular-related disorders
WO1999010004A3 (en) Regulation of muscle tissues by hedgehog-like polypeptides, and formulations and uses related thereto
MY117377A (en) Chlorofluorocarbon-free mometasone furote aerosol formulations
WO2002058589A3 (en) Agents and methods for promoting bone growth
Ten Cate Physiological resorption of connective tissue associated with tooth eruption
AU3475495A (en) Process for producing recombinant proteins, plasmids and modified cells
MX9606610A (en) INCREASED PRODUCTION OF 'beta'-GALACTOSIDASE IN ASPERGILLUS ORYZAE.
UA35566C2 (en) Drug for preventing and treating disordered lipoid and cholesterol metabolism and method for preventing and treating these disorders
WO1998037873A3 (en) Method for reducing secretion of apolipoprotein b in animals by administering conjugated linoleic acid
EP0652755A1 (en) Therapeutic use of phosphoryl-l-serine-n-acyl-sphingosine.
McGuire et al. Properties of rheumatoid and normal synovial tissue in vitro and cells derived from them: production of prostaglandins and collagenase in response to factors derived from cultured blood mononuclear cells and from synovium

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AT AU BB BG BR CA CH CS DE DK ES FI GB HU JP KP KR LK LU MG MN MW NL NO PL RO RU SD SE US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR SN TD TG

EX32 Extension under rule 32 effected after completion of technical preparation for international publication

Free format text: KZ

WWE Wipo information: entry into national phase

Ref document number: 1993901159

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2126103

Country of ref document: CA

AK Designated states

Kind code of ref document: A3

Designated state(s): AT AU BB BG BR CA CH CS DE DK ES FI GB HU JP KP KR LK LU MG MN MW NL NO PL RO RU SD SE US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
LE32 Later election for international application filed prior to expiration of 19th month from priority date or according to rule 32.2 (b)
WWP Wipo information: published in national office

Ref document number: 1993901159

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 1993901159

Country of ref document: EP